Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US

Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US

BackgroundThe effectiveness of Sacituzumab Govitecan (SG) for metastatic triple-negative breast cancer (mTNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on mTNBC from the Chinese and United States (US) perspective.MethodsA partitioned survival model was developed to compare...

Full description

Bibliographic Details
Main Authors: Jigang Chen, Mingyang Han, Aihua Liu, Bo Shi
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
economic evaluation
Sacituzumab Govitecan
breast cancer
China
US
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.734594/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.734594/full

Similar Items